Rhelion Life Sciences (RHEL.CN) reported a first-quarter net loss of C$1.9 million, compared with C$1 million, a year earlier.
Revenue decreased to C$0.2 million in the three months ended June 30, 2026, compared with C$0.6 million, a year-ago.
Shares of the company were last seen unchanged at C$0.025 on the Canadian Securities Exchange.